|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1800 CONCORD PIKE, P.O. BOX 15437 |
Address2 |
|
| City | WILMINGTON |
State | DE |
Zip Code | 19850-5437 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 54073-12
|
||||||||
|
6. House ID# 349750000
|
||||||||
| TYPE OF REPORT | 8. Year | 2023 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Jamie Bell |
Date | 7/20/2023 7:10:12 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Implementation of the Inflation Reduction Act (IRA) -- with specific focus on drug negotiation (orphan drug exemption language), Medicare Part D reform, and inflation penalties.
Issues related to the orphan drug exclusion of the Inflation Reduction Act.
Issues related to clinical trial diversity.
Issues related to lung cancer screening.
Issues related to drug shortages.
Issues related to workforce development.
Issues related to the biopharmaceutical supply chain.
Issues related to reauthorization of the Pandemics and All-Hazards Preparedness Act (PAHPRA).
Issues related to rare disease patients with employer sponsored insurance.
Issues related to Reform of pharmacy benefit managers.
Issues related to the Cancer Moonshot Initiative.
Issues related to Medicare reimbursement of patient navigators.
Issues related to 340B.
Issues related to drug shortages.
Issues related to electronic prescribing labeling.
FDA modernization policy issues.
Reauthorization of newborn screening programs.
General issues related to rare disease and orphan drugs.
General issues related to health equity in rare disease and clinical trials.
General issues related to diagnostics for patients with rare diseases.
H.R. 1503, Prescription Information Modernization Act of 2023.
H.R. 2407, Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), White House Office, Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Helen |
Dwight |
|
|
|
Aaron |
Hunter |
|
|
|
Elizabeth |
Brooks |
|
|
|
Katie |
Jones |
|
|
|
Sarah |
Arbes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Issues related to implementation of H.R.5376 - Inflation Reduction Act of 2022 (Public Law No. 117-169).
Issues related to low volume Diagnosis Related Groups (DRGs) and rare therapies.
Orphan drug exemption of the Implementation of the Inflation Reduction Act, Pub. L. 117-169.
CMS Comment Solicitation on Possible Mechanisms to Address Rare Diseases and Conditions Represented by Low Volumes within the MS-DRG Structure.
Centers for Medicare and Medicaid Innovation (CMMI) policy issues.
Issues pertaining to implementation of the Inflation Reduction Act, H.R.5376 - Inflation Reduction Act of 2022 (Public Law No. 117-169).
Medicare patient access to rare disease therapies, Part B and Part D drugs.
Value-based payment arrangements.
Efforts to improve coding, coverage, and access for rare disease therapies.
General issues related to diagnostic reimbursement.
S 2085, the Medicare Multi-Cancer Early Detection Screening Coverage Act.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Helen |
Dwight |
|
|
|
Aaron |
Hunter |
|
|
|
Elizabeth |
Brooks |
|
|
|
Katie |
Jones |
|
|
|
Sarah |
Arbes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Issues related to Pharmacy Benefit Managers (PBMs).
Issues related to 340B reform.
Issues related to prescription drug shortages.
Issues related to the orphan drug exclusion of the Inflation Reduction Act.
Issues related to implementation of H.R.5376 - Inflation Reduction Act of 2022 (Public Law No. 117-169).
S. 113, Prescription Pricing for the People Act of 2023.
S. 127, Pharmacy Benefit Manager Transparency Act of 2023.
S. 1038, Drug Price Transparency in Medicaid Act of 2023.
H.R. 1613 Drug Pricing Transparency in Medicaid Act of 2023.
H.R. 3561, PATIENT Act of 2023.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Helen |
Dwight |
|
|
|
Aaron |
Hunter |
|
|
|
Elizabeth |
Brooks |
|
|
|
Katie |
Jones |
|
|
|
Sarah |
Arbes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Issues related to the Orphan Drug Tax Credit.
Issues related to the deduction of research and development expenditures.
H.R. 1350, Camerons Law.
H.R.2673, American Innovation and R&D Competitiveness Act of 2023.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Helen |
Dwight |
|
|
|
Elizabeth |
Brooks |
|
|
|
Katie |
Jones |
|
|
|
Aaron |
Hunter |
|
|
|
Sarah |
Arbes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
H.R. 4368, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024.
H. Rept. 118-24, S. Rept. 118-44 -- Agriculture, Rural Development, and Food & Drug Administration appropriations; Issues related to the Labor, Health and Human Services, and Education appropriations.
S. 2131, To provide for a limitation on availability of funds for Independent Agencies, National Historical Publications and Records Commission, Grants Program for fiscal year 2024.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Helen |
Dwight |
|
|
|
Aaron |
Hunter |
|
|
|
Elizabeth |
Brooks |
|
|
|
Katie |
Jones |
|
|
|
Sarah |
Arbes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Pharmaceutical IP and patent reform.
S. 142, Preserve Access to Affordable Generics and Biosimilars Act.
S. 150, Affordable Prescriptions for Patients Act of 2023.
S. 1214, RARE Act.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Helen |
Dwight |
|
|
|
Aaron |
Hunter |
|
|
|
Elizabeth |
Brooks |
|
|
|
Katie |
Jones |
|
|
|
Sarah |
Arbes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code INS
16. Specific lobbying issues
Pharmacy Benefit Managers (PBM) reform.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Helen |
Dwight |
|
|
|
Katie |
Jones |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |